Login Register Cart 0
Generic placeholder image

Current Vascular Pharmacology

Editor-in-Chief

ISSN (Print): 1570-1611
ISSN (Online): 1875-6212

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Imbalance of Pro- and Anti-inflammatory Cytokines Induced Different Types of Recurrent Atrial Arrhythmias after Drug Eluting Coronary Stent Implantation

Author(s): Xia Li*, Haibo Hu, Dianxuan Guo, Youdong Hu, Hualan Zhou, Ying Chen and Xiang Fang

Volume 20, Issue 5, 2022

Published on: 21 September, 2022

Page: [447 - 456] Pages: 10

DOI: 10.2174/1570161120666220831094507

Price: $65

Abstract

Background: Atrial arrhythmias are associated with an increased risk of stroke and death in the elderly. The risk and predictive factors of recurrent atrial arrhythmias in elderly patients after coronary stenting are not well known.

Objective: This research sought to investigate the roles of pro- and anti-inflammatory cytokine imbalances in different types of recurrent atrial arrhythmias in elderly patients defined as individuals aged 65 years or older after sirolimus eluting stent (Cordis, Warren, New Jersey) implantation.

Methods: We measured interleukin-1β (IL-1β), interleukin-6 (IL-6), interleukin-8 (IL-8), tumor necrosis factor-α (TNF-α), interleukin-10 (IL-10), interleukin-17 (IL-17), interleukin-13 (IL-13) and interleukin- 37 (IL-37) in elderly patients with recurrent atrial arrhythmias and assessed the impact of pro- and antiinflammatory cytokine imbalances on recurrent atrial arrhythmias in elderly patients after coronary stenting.

Results: Levels of IL-1 β, IL-6, IL-8, and TNF-α were remarkably increased (p<0.001), and IL-10, IL- 17, IL-13, and IL-37 were remarkably lowered (p<0.001) in elderly patients with recurrent atrial arrhythmias after coronary stent implantation. Imbalance of pro- and anti-inflammatory cytokines induced recurrent atrial arrhythmias after coronary stenting. Pro- and anti-inflammatory cytokine imbalances may be used to identify elderly patients who have an increased risk of developing recurrent atrial arrhythmias after coronary stenting.

Conclusion: The imbalance of pro- and anti-inflammatory cytokines was associated with recurrent atrial arrhythmias in elderly patients after coronary stenting. Pro- and anti-inflammatory cytokines may be clinically useful biomarkers for predicting recurrent atrial arrhythmias in elderly patients after coronary stent implantation.

Keywords: Pro-inflammatory cytokines, anti-inflammatory cytokines, recurrent atrial arrhythmias, elderly, stent implantation, coronary stenting

« Previous
Graphical Abstract

[1]
Monnerat G, Alarcón ML, Vasconcellos LR, et al. Macrophage-dependent IL-1β production induces cardiac arrhythmias in diabetic mice. Nat Commun 2016; 7: 13344-59.
[http://dx.doi.org/10.1038/ncomms13344] [PMID: 27882934]
[2]
Alí A, Boutjdir M, Aromolaran AS. Aromolaran cardiolipotoxicity, inflammation, and arrhythmias: Role for interleukin-6 molecular mechanisms. Front Physiol 2019; 9: 1866-85.
[http://dx.doi.org/10.3389/fphys.2018.01866] [PMID: 30666212]
[3]
Vm M, AL S, Aa A, et al. Circulating interleukin-18: Association with IL-8, IL-10 and VEGF serum levels in patients with and without heart rhythm disorders. Int J Cardiol 2016; 215: 105-9.
[http://dx.doi.org/10.1016/j.ijcard.2016.04.002]
[4]
Zuo S, Li L, Ruan Y, et al. Acute administration of tumour necrosis factor-α induces spontaneous calcium release via the reactive oxygen species pathway in atrial myocytes. Europace 2018; 20(8): 1367-74.
[http://dx.doi.org/10.1093/europace/eux271] [PMID: 29045723]
[5]
Kondo H, Abe I, Gotoh K, et al. Interleukin 10 treatment ameliorates high-fat diet-induced inflammatory atrial remodeling and fibrillation. Circ Arrhythm Electrophysiol 2018; 11(5): e006040.
[http://dx.doi.org/10.1161/CIRCEP.117.006040] [PMID: 29748196]
[6]
Francis Stuart SD, De Jesus NM, Lindsey ML, Ripplinger CM. The crossroads of inflammation, fibrosis, and arrhythmia following myocardial infarction. J Mol Cell Cardiol 2016; 91: 114-22.
[http://dx.doi.org/10.1016/j.yjmcc.2015.12.024] [PMID: 26739214]
[7]
Pan Y, Wen X, Hao D, et al. The role of IL-37 in skin and connective tissue diseases. Biomed Pharmacother 2020; 122: 109705.
[http://dx.doi.org/10.1016/j.biopha.2019.109705] [PMID: 31918276]
[8]
Simon T, Taleb S, Danchin N, et al. Circulating levels of interleukin-17 and cardiovascular outcomes in patients with acute myocardial infarction. Eur Heart J 2013; 34(8): 570-7.
[http://dx.doi.org/10.1093/eurheartj/ehs263] [PMID: 22956509]
[9]
Taleb S, Romain M, Ramkhelawon B, et al. Loss of SOCS3 expression in T cells reveals a regulatory role for interleukin-17 in atherosclerosis. J Exp Med 2009; 206(10): 2067-77.
[http://dx.doi.org/10.1084/jem.20090545] [PMID: 19737863]
[10]
Hamzei Taj S, Le Blon D, Hoornaert C, et al. Targeted intracerebral delivery of the anti-inflammatory cytokine IL13 promotes alternative activation of both microglia and macrophages after stroke. J Neuroinflammation 2018; 15(1): 174.
[http://dx.doi.org/10.1186/s12974-018-1212-7] [PMID: 29866203]
[11]
Cardilo-Reis L, Gruber S, Schreier SM, et al. Interleukin‐13 protects from atherosclerosis and modulates plaque composition by skewing the macrophage phenotype. EMBO Mol Med 2012; 4(10): 1072-86.
[http://dx.doi.org/10.1002/emmm.201201374] [PMID: 23027612]
[12]
Theoharides TC, Tsilioni I, Conti P. Mast cells may regulate the anti-inflammatory activity of IL-37. Int J Mol Sci 2019; 20(15): 3701.
[http://dx.doi.org/10.3390/ijms20153701] [PMID: 31362339]
[13]
Xu D, Wang A, Jiang F, Hu J, Zhang X. Effects of interleukin-37 on cardiac function after myocardial infarction in mice. Int J Clin Exp Pathol 2015; 8(5): 5247-51. Available from: www.ijcep.com
[PMID: 26191225]
[14]
Nishida S, Nagamine H, Tanaka Y, Watanabe G. Protective effect of basic fibroblast growth factor against myocyte death and arrhythmias in acute myocardial infarction in rats. Circ J 2003; 67(4): 334-9.
[http://dx.doi.org/10.1253/circj.67.334] [PMID: 12655165]
[15]
Lazarus A, Varin J, Babuty D, Anselme F, Coste J, Duboc D. Long-term follow-up of arrhythmias in patients with myotonic dystrophy treated by pacing. J Am Coll Cardiol 2002; 40(9): 1645-52.
[http://dx.doi.org/10.1016/S0735-1097(02)02339-2] [PMID: 12427418]
[16]
Goodacre S, Irons R. Atrial arrhythmias. BJM 2002; 324: 594.
[http://dx.doi.org/10.1136/bmj.324.7337.594]
[17]
Najjari M, Vaezi G, Hojati V, Mousavi Z, Bakhtiarian A, Nikoui V. Involvement of IL-1β and IL-6 in antiarrhythmic properties of atorvastatin in ouabain-induced arrhythmia in rats. Immunopharmacol Immunotoxicol 2018; 40(3): 256-61.
[http://dx.doi.org/10.1080/08923973.2018.1440592] [PMID: 29486618]
[18]
Kern KB, Berg RA, Hilwig RW, Larson DF, Gaballa MA. Myocardial cytokine IL-8 and nitric oxide synthase activity during and after resuscitation: Preliminary observations in regards to post-resuscitation myocardial dysfunction. Resuscitation 2008; 77(3): 401-9.
[http://dx.doi.org/10.1016/j.resuscitation.2008.01.026] [PMID: 18359140]
[19]
Santoro F, Tarantino N, Ferraretti A, et al. Serum interleukin 6 and 10 levels in Takotsubo cardiomyopathy: Increased admission levels may predict adverse events at follow-up. Atherosclerosis 2016; 254: 28-34.
[http://dx.doi.org/10.1016/j.atherosclerosis.2016.09.012] [PMID: 27680775]
[20]
Ke Y, Liu K, Huang GQ, et al. Anti-inflammatory role of IL-17 in experimental autoimmune uveitis. J Immunol 2009; 182(5): 3183-90.
[http://dx.doi.org/10.4049/jimmunol.0802487] [PMID: 19234216]
[21]
Gaiolla RD, Domingues MAC, Niéro-Melo L, de Oliveira DE. Serum levels of interleukins 6, 10, and 13 before and after treatment of classic Hodgkin lymphoma. Arch Pathol Lab Med 2011; 135(4): 483-9.
[http://dx.doi.org/10.5858/2010-0060-OA.1] [PMID: 21466366]
[22]
Li C, Ji H, Cai Y, et al. Serum interleukin-37 concentrations and HBeAg seroconversion in chronic HBV patients during telbivudine treatment. J Interferon Cytokine Res 2013; 33(10): 612-8.
[http://dx.doi.org/10.1089/jir.2013.0001] [PMID: 23697556]
[23]
Melenovsky V, Lip GYH. Interleukin-8 and atrial fibrillation. Europace 2008; 10(7): 784-5.
[http://dx.doi.org/10.1093/europace/eun154] [PMID: 18523030]
[24]
Klein RM, Vester EG, Brehm MU, et al. Inflammation of the myocardium as an arrhythmia trigger. Z Kardiol 2000; 89(3) (Suppl. 3): 24-35.
[http://dx.doi.org/10.1007/PL00022871] [PMID: 10810782]
[25]
Saito J, Niwano S, Niwano H, et al. Electrical remodeling of the ventricular myocardium in myocarditis: Studies of rat experimental autoimmune myocarditis. Circ J 2002; 66(1): 97-103.
[http://dx.doi.org/10.1253/circj.66.97] [PMID: 11999674]
[26]
Boos CJ, Anderson RA, Lip GYH. Is atrial fibrillation an inflammatory disorder? Eur Heart J 2006; 27(2): 136-49.
[http://dx.doi.org/10.1093/eurheartj/ehi645] [PMID: 16278230]
[27]
Aviles RJ, Martin DO, Apperson-Hansen C, et al. Inflammation as a risk factor for atrial fibrillation. Circulation 2003; 108(24): 3006-10.
[http://dx.doi.org/10.1161/01.CIR.0000103131.70301.4F] [PMID: 14623805]
[28]
Hagiwara N. Inflammation and atrial fibrillation. Circ J 2010; 74(2): 246-7.
[http://dx.doi.org/10.1253/circj.CJ-09-0986] [PMID: 20065606]
[29]
Harada M, Van Wagoner DR, Nattel S. Role of inflammation in atrial fibrillation pathophysiology and management. Circ J 2015; 79(3): 495-502.
[http://dx.doi.org/10.1253/circj.CJ-15-0138] [PMID: 25746525]
[30]
Yao SY, Chu JM, Chen KP, et al. Inflammation in lone atrial fibrillation. Clin Cardiol 2009; 32(2): 94-8.
[http://dx.doi.org/10.1002/clc.20290] [PMID: 19215009]
[31]
Xia HJ, Dai DZ, Dai Y. Up-regulated inflammatory factors endothelin, NFκB, TNFα and iNOS involved in exaggerated cardiac arrhythmias in l-thyroxine-induced cardiomyopathy are suppressed by darusentan in rats. Life Sci 2006; 79(19): 1812-9.
[http://dx.doi.org/10.1016/j.lfs.2006.06.007] [PMID: 16822527]
[32]
Albanesi C, Fairchild HR, Madonna S, et al. IL-4 and IL-13 negatively regulate TNF-alpha- and IFN-gamma-induced beta-defensin expression through STAT-6, suppressor of cytokine signaling (SOCS)-1, and SOCS-3. J Immunol 2007; 179(2): 984-92.
[http://dx.doi.org/10.4049/jimmunol.179.2.984] [PMID: 17617590]
[33]
Abulkhir A, Samarani S, Amre D, et al. A protective role of IL-37 in cancer: A new hope for cancer patients. J Leukoc Biol 2017; 101(2): 395-406.
[http://dx.doi.org/10.1189/jlb.5RU0816-341R] [PMID: 27881603]
[34]
Gossart A, Letourneur D, Gand A, et al. Mitigation of monocyte driven thrombosis on cobalt chrome surfaces in contact with whole blood by thin film polar/hydrophobic/ionic polyurethane coatings. Biomaterials 2019; 217: 119306.
[http://dx.doi.org/10.1016/j.biomaterials.2019.119306] [PMID: 31271854]
[35]
Greque GV, Serrano CV Jr, Strunz CM, et al. Preprocedural statin therapy, inflammation, and myocardial injury in low-risk stable coronary artery disease patients submitted to coronary stent implantation. Catheter Cardiovasc Interv 2016; 87(2): 222-9.
[http://dx.doi.org/10.1002/ccd.24937] [PMID: 23592528]
[36]
Rai V, Agrawal DK. Immunomodulation of IL-33 and IL-37 with Vitamin D in the neointima of coronary artery: A comparative study between balloon angioplasty and stent in hyperlipidemic microswine. Int J Mol Sci 2021; 22(16): 8824.
[http://dx.doi.org/10.3390/ijms22168824] [PMID: 34445530]
[37]
Li W, Li S, Li X, Jiang S, Han B. Interleukin-37 elevation in patients with atrial fibrillation. Clin Cardiol 2017; 40(2): 66-72.
[http://dx.doi.org/10.1002/clc.22630] [PMID: 28244597]

Rights & Permissions Print Cite
Article Metrics
3
© 2024 Bentham Science Publishers | Privacy Policy